Roasted soybeans and an estrogenic growth promoter affect the thyroid status of beef steers.
We investigated the interactive effects of a roasted soybean (RSB)-supplemented diet and an estrogen ear implant [Synovex-S (SYN), 20 mg estradiol benzoate + 200 mg progesterone] in young beef steers on measures of thyroid status before and after challenge injections of thyrotropin-releasing hormone (TRH) + growth hormone-releasing hormone (GHRH). Twenty steers (body weight 255 +/- 5 kg) were assigned to the following treatments: 1) no SYN and a soybean meal-supplemented diet, 2) no SYN and a RSB-supplemented diet, 3) plus SYN and soybean meal, and 4) plus SYN and RSB. Steers were individually fed 1.13 MJ metabolizable energy/kg metabolic body wt daily of an 18% protein diet. After a 5-wk growth period, all steers were challenged (intravenous injection) over a 3-wk period with three dose levels of a combination of TRH + GHRH (0.1 + 0.01, 1.0 + 0.1 and 2.5 + 0.25 microg/kg body wt). There were no dose by SYN or RSB interactions. Across dose levels, values for baseline plasma thyroid-stimulating hormone (TSH) were 0.37, 0.35, 0.61 and 0.33 microg/L for treatments 1, 2, 3 and 4, respectively (SYN, P < 0.07; RSB, P < 0.01; SYN x RSB, P < 0.03; SEM 0.06). Net areas under the response curve for TSH were 66.4, 51.3, 91.4 and 64.4 (microg/L) x min, respectively (RSB, P < 0.08; SEM 12.0). Similar treatment effects and/or numerical differences after challenge were noted for thyroxine (T4) but not triiodothyronine (T3). Baseline (2.22 vs. 2.00 microg/L, P < 0.02) and peak (3.07 vs. 2.03 microg/L, P < 0.03) T3 concentrations were less for steers fed RSB than for steers fed soybean meal. This study indicates that in young growing beef steers, SYN increases TSH release from the adenohypophysis and that the primary effect of RSB is reduced plasma T3, possibly through an effect on peripheral T4 deiodination.
Rumsey
T S
TS
Livestock and Poultry Sciences Institute, Agricultural Research Service, U.S. Department of Agriculture, Beltsville, MD 20705-2350, USA.
Elsasser
T H
TH
Kahl
S
S
D000821:Animal Feed; D000818:Animals; D002417:Cattle / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005511:Food Handling; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D006358:Hot Temperature; D007275:Injections, Intravenous / Q000662:veterinary; D008297:Male; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology*; D013025:Glycine max / Q000009:adverse effects; D013961:Thyroid Gland / Q000187:drug effects / Q000502:physiology*; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D004338:Drug Combinations; D004343:Drug Implants; D014284:Triiodothyronine; D011374:Progesterone; D004958:Estradiol; D013973:Thyrotropin-Releasing Hormone; C025370:estradiol benzoate, progesterone drug combination; D013972:Thyrotropin; D013007:Growth Hormone-Releasing Hormone; D013974:Thyroxine